Eupraxia Pharmaceuticals Inc (EPRX-T) Profile

Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Name	Title
Paul Brennan	Other Executive Officer
Mark Kowalski	Chief Medical Officer
James A. Helliwell	CEO/Co-Founder/Director
Amanda Malone	Chief Scientific Officer/COO
Alexander Rothwell	CFO

More from The Globe

Bullish on Expeditors International of Washington Inc.

Monica Rizk

Yesterday

Small caps to watch: Boyd Group shares dive after earnings. Plus, Total Energy Services, AGT Food, Goeasy, Algoma Steel and more

Yesterday

${"Id":780514,"Name":"Don't expect big lift in stocks due to 'January Effect': Stephenson","Desc":"John Stephenson, President and CEO, Stephenson & Company discusses the so-called \"January effect\" and whether he thinks it will make a difference for markets in 2016.","ShortDesc":"John Stephenson, President and CEO, Stephenson & Company discusses the so-called \"January effect\" and whether he thinks it will make a...","Type":"segment","Episode":null,"AgvotCode":"E","AgvotDisclaimer":null,"QfrCode":"G","AiringOrder":null,"BroadcastDate":"2016-01-04","BroadcastTime":"08:10:15","BroadcastDateTime":"2016-01-04T08:10:15-05:00","LastModifiedDateTime":"2016-01-04T14:23:28Z","GameId":null,"Album":null,"Genres":[{"Id":154,"Name":"Commentary"},{"Id":40,"Name":"Investing"}],"Keywords":[{"Id":66203,"Name":"john stephenson","Count":139},{"Id":64202,"Name":"President","Count":273},{"Id":61326,"Name":"CEO","Count":342},{"Id":78657,"Name":"Stephenson & Company","Count":61},{"Id":70011,"Name":"january effect","Count":1},{"Id":61275,"Name":"markets","Count":1303},{"Id":61269,"Name":"stocks","Count":553},{"Id":75870,"Name":"tax-loss selling","Count":5},{"Id":63123,"Name":"small caps","Count":54},{"Id":63054,"Name":"prices","Count":20},{"Id":69699,"Name":"december","Count":2},{"Id":64558,"Name":"january","Count":0}],"Tags":[],"Images":[{"Type":"thumbnail","Url":"http://images.9c9media.com/image_asset/2016_1_4_a0629a30-951c-0133-524d-34b52f6f1279_jpg_940x529.jpg","Width":940,"Height":529}],"Authentication":{"Required":false,"Resources":null},"RatingWarnings":[],"People":[],"Funding":null,"MusicLabels":[],"BroadcastNetworks":[]}$